Partial tandem duplication of MLL (MLL-PTD) characterizes acute myeloid leukemia (AML) patients often with a poor prognosis. To understand the order of occurrence of MLL-PTD in relation to other major AML mutations and to identify novel mutations that may be present in this unique AML molecular subtype, exome and targeted sequencing was performed on 85 MLL-PTD AML samples using HiSeq-2000. Genes involved in the cohesin complex (STAG2), a splicing factor (U2AF1) and a poorly studied gene, MGA were recurrently mutated, whereas NPM1, one of the most frequently mutated AML gene, was not mutated in MLL-PTD patients. Interestingly, clonality analysis suggests that IDH2/1, DNMT3A, U2AF1 and TET2 mutations are clonal and occur early, and MLL-PTD likely arises after these initial mutations. Conversely, proliferative mutations (FLT3, RAS), typically appear later, are largely subclonal and tend to be unstable. This study provides important insights for understanding the relative importance of different mutations for defining a targeted therapeutic strategy for MLL-PTD AML patients.
INTRODUCTION
Acute myeloid leukemia (AML) is a highly malignant hematopoietic disorder affecting annually~13 000 adults in the United States. 1, 2 It is a heterogeneous group of diseases classified by distinct morphologies, karyotypes and molecular subtypes. A particularly interesting AML subtype is the AML cases with partial tandem duplication of the MLL gene (MLL-PTD), characterized by the internal partial tandem duplication of exons 3-9 or 3-11 in the MLL gene. MLL-PTD often occurs in elderly patients and consists of 3-5% of de novo AML. In particular, patients carrying MLL-PTD often have a bad prognosis. [3] [4] [5] [6] MLL-PTD is generally believed to act as an oncogenic driver by modulating expression of HOX genes. However, mice carrying Mll-PTD alone do not develop spontaneous leukemia, 7 unless they are crossed with those harboring another major leukemogenic driver (for example, Flt3-ITD), 8 suggesting that by itself Mll-PTD is not sufficient to transform hematopoietic cells. In addition, the mutational landscape of MLL-PTD AML has not been fully explored as this subtype constitutes only 9 of the 200 TCGA-AML samples. 9, 10 Identification of collaborating driver mutations and, subsequently, the underlying molecular mechanisms driving this AML subtype will enhance our understanding of this devastating disease.
AML is viewed as a disease formed by sequential acquisition of a number of mutations in long-lived, self-renewing hematopoietic stem cells. [10] [11] [12] Investigators have recently proposed that the order of mutational acquisition has a substantial impact on clinical response in myeloid neoplasms. 13 In addition, the order of acquiring mutations has profound implications for the design of therapeutic strategies, where the greatest therapeutic benefits are most likely gained by targeting the earliest initiating mutation. In the context of MLL-PTD AML, deciphering the evolutionary timeline of the acquisition of this gene is important. A strategy based on DOT1L inhibition was recently proposed for treating MLL-rearranged (MLL fusion/MLL-PTD) leukemia, 14, 15 and the effectiveness of this strategy is reliant on an underlying assumption that the alteration of MLL occurs as an early initiating, clonal mutation. To examine the ordering of different mutations in this rare but clinically important AML subtype and to identify novel uncharacterized mutations, we performed whole-exome and targeted sequencing on 85 MLL-PTD AML patients.
MATERIALS AND METHODS
Exome sequencing and target capture sequencing AML samples were purified using Ficoll paque to enrich for mononuclear cells. DNA samples were processed for whole-exome sequencing using SureSelect XT or XT2 (for targeted sequencing) Target Enrichment System (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's protocol. Sequence data were generated on Illumina HiSeq-2000 platform. Sequence reads were aligned to human reference genome hg19 for both whole-exome and targeted sequencing libraries using Novoalign V3.01.02 (http://www. novocraft.com/) with parameter -F ILMFQ to reflect properly base sequencing quality of our data sets. SAMtools (Version 0.1.19) was used to remove PCR duplicates. 1 Somatic SNV detection (with matched remission samples)
To identify somatic single-nucleotide variants (SNV) in patients with matched remission samples, software MuTect (Version 1.1.4) 16 was utilized with default parameters. Annotation files corresponding to COSMIC database (hg19-cosmic-v54-120711.vcf) and dbSNP database (dbsnp-132-b37.leftAligned.vcf) were retrieved from MuTect website (http://www. broadinstitute.org/cancer/cga/mutect-download) and utilized with MuTect software for variant calls. Identified SNV passing the filtering criteria were retained and used for downstream analysis.
Generation of false SNV list from panel of normal samples
Artifact detection mode of Mutect program was utilized to generate a list of potential sequencing artifacts, mapping errors and common SNPs from our in-house database of 240 normal samples (manually curated). Variants that were positively identified in the normal samples by Mutect were compiled to generate a putative list of false somatic SNVs. Somatic SNVs detected from each normal-tumor pair were discarded if they were similarly found in this list of false somatic SNVs.
See Supplementary data for a full description of Materials and Methods.
RESULTS

Mutational landscape of MLL-PTD AML
To generate a mutational spectrum for MLL-PTD AML, we initially searched for cooperative driving events by performing exome sequencing of genomic DNA of five MLL-PTD AML patients at diagnosis, relapse and at complete remission (Supplementary Table 1 ). Driver mutations (for example, FLT3, DNMT3A) were clearly identified in all patients (Supplementary Table 2 ). The analysis of the mutational spectrum indicates the dominance of C4T transitions, which is in line with the finding of TCGA-AML and is likely caused by spontaneous deamination of methylcytosine 17 related with aging (Supplementary Figure 1a) .
The potential clonal architecture and clonal evolution were subsequently inferred from the mutational data ( Supplementary  Figures 1b and c) . All of the patients shared a similar clonal evolutionary pattern: despite achieving complete clinical hematologic remission, the original founder clone of AML cells or the pre-malignant clone survived chemotherapy, gained additional mutations and reemerged at relapse (Supplementary Figure 1c) . We next extended our study to a larger group of MLL-PTD AML patients (prevalence cohort). Mutated genes identified from the discovery cohort and selected leukemia/cancer-related genes (Supplementary Table 3 , 530 genes) were chosen for targeted sequencing on an additional 80 AML patients carrying the MLL-PTD mutation (Supplementary Tables 4-6) . A 259X mean sequencing read depth was achieved for the prevalence cohort (Supplementary Figure 2) . A dominant C4T transition mutation pattern was similarly found in the prevalence cohort, and mutation signature 1b was identified as the dominant mutational signature (Supplementary Figure 3 , Alexandrov et al. 18 ). At least one well-known oncogenic driver mutation was identified in over 90% of the MLL-PTD patients (Figure 1, Supplementary Figure 4) . Recurrent hotspot mutations were noted in IDH1/2, U2AF1, NRAS and FLT3, suggesting a potential gain-of-function effect of these alterations. On the other hand, mutations of RUNX1, TET2, WT1, STAG2 and ASXL1 were largely scattered throughout these genes and tended to be inactivating, implying their potential tumor suppressor roles in AML. Compared with the mutational landscape of 200 TCGA-AML samples, 9 several well-known leukemic drivers ( Figure 2 , Supplementary Table 7) as well as a few novel genes like MGA (9%) and members of the NOTCH family were enriched in MLL-PTD-positive samples (Supplementary Figure 5) . Remarkably, no mutations of NPM1 were found in our patient cohort, although it is one of the most frequently mutated AML genes identified by TCGA (27%). 9 The frequently mutated genes that we identified Figure 4 ). Only canonical hotspots or fs/stop-gain mutations found in both diagnosis and remission were considered as 'mutation also present at remission' .
were classified into several categories: epigenetic regulators, RAS-RTK pathway, transcriptional factors, cohesin complex and splicing factors.
Mutations of epigenetic regulators
In line with earlier sequencing studies of other AML subtypes and the TCGA-AML-sequencing project, 9 DNMT3A was the most often mutated epigenetic regulator (25%): the well-known hotspot mutation R882H was found in 12 patients; S714C/F mutation was detected in three patients. A dominant-negative role of these missense mutations has been found and a tumor-suppressor role of DNMT3A has been recently proposed. [19] [20] [21] In addition, frameshift and stop-gain DNMT3A mutations were found in six patients. IDH1/IDH2 hotspot mutations were identified in 31% of patients (R140Q (13 cases) or R172K (3 cases) in IDH2 and at R132 in IDH1 (4 cases)). The TET family was the third most prominently mutated epigenetic regulator (TET1 (5%), TET2 (16.3%, six frameshift and three stop-gain)). In line with previous observations, 3 mutually exclusive mutational patterns were noted between IDH1/2 and TET1/2 (Supplementary Figure 6) . Mutations of epigenetic regulators also occurred in polycomb-associated proteins (EZH2, ASXL family members, Supplementary Figure 7 ), chromatin remodelers (ARID2, ARID1A), genes associated with histone acetylation (CREBBP, EP300, KAT6A, KAT6B) and histone methylation (MLL2, MLL3, MLL4).
Mutations in the RAS-FLT3 pathway are subclonal and tend to be unstable The proliferation-related pathway was extensively mutated, with 54 of 80 MLL-PTD patients (67.5%) carrying at least one mutation of the proliferative genes ( Figure 3a) . Specifically, FLT3 mutations were found in 46% of patient samples. These mutations included: #1, internal tandem-duplications (ITD) in exon 14 (41 ITD mutations in 27 patients, Supplementary Table 8); #2, well-known hotspot mutations located in the kinase domain (D835/D839); #3, recurrent in-frame (p.836_837) deletion in the kinase domain ( Figure 3b) ; #4, novel missense mutations in the juxta-membrane domain. Notably, some FLT3-ITD patients had more than one type of ITD insertion, which probably reflects the existence of multiple subclones in their leukemia (Supplementary Table 8 ).
The presence of several ITD mutations in different subclones signifies the prominent role of FLT3-ITD in accelerating clonal expansion.
Importantly, mutations in FLT3 and other proliferationrelated genes were largely subclonal with median variant allele-frequencies (VAFs) ranging from~0.10-0.15 ( Figure 3c ). Comparatively, mutations of epigenetic regulators (DNMT3A, IDH1, IDH2, TET2), transcriptional factors (RUNX1, WT1), as well as a splicing factor U2AF1 tended to have relatively high VAF (~0.35-0.45, Figure 3c , Supplementary Figure 8 ), suggesting they occurred earlier during leukemic evolution. Notably, clones carrying FLT3 mutations were often found to be unstable and frequently expanded or diminished during progression of disease (6 of 13 patients who had matched relapse samples for analysis, Figure 3d , Supplementary Figure 9 ). Interestingly, mutations driving proliferation also appeared to be interchangeable during the evolution of disease. In patient CH002, for example, the clone carrying the Q61R NRAS mutation was readily observed at diagnosis, but declined beyond the limits of detection in the relapse sample (Figure 3e ). In contrast, the clone carrying the FLT3 D839R mutation was identified in the relapse sample while it was below the limits of detection (~400X) in the diagnosis sample ( Figure 3e and f). Similarly, in patient GR019, two FLT3-ITDs (L610delins and N609delins) that were initially observed at diagnosis, were not found at relapse. Coupled with this, a relatively strong surge of a clone carrying another FLT3-ITD (Y597delins) occurred in the relapse (Figure 3e ). Furthermore, multiple subclonal mutations carrying different proliferation driving mutations could often be found in the patients' AML ( Figure 3g ). Collectively, these results support a model in which diverse proliferative drivers were independently acquired in different subclones derived from the founder clone.
Recurrent mutations of cohesin genes and splicing factors
Besides the well-established role in the control of separation of the sister chromatids during cell division, cohesin proteins also have important roles in the maintenance of genome stability, DNA damage repair and regulation of gene transcription. Recurrent mutations of genes in the cohesin complex have been reported in a variety of cancers, including myelodysplastic syndromes, myeloproliferative neoplasms and AML. 22, 23 Herein, we also found highly prevalent mutations of the cohesin genes (STAG2 (16.3%), SMC1A (6.3%), SMC3 (1%) and RAD21 (1%)) and CTCF (6%, a transcription factor associated with the cohesin complex). In totality, the cohesin pathway is more frequently mutated in MLL-PTD patients (26%) than the AML samples from either TCGA (13%, Po0.01) or a meta-analysis of 1000 AML (9.1%, Po0.0001). 24 Remarkably, an extremely high proportion of the mutations had a strong tendency to disrupt the coding sequence (eight stop-gain, two frameshift and two splice-site mutations) in STAG2 (Figure 4a ), emphasizing its crucial tumor-suppressor role in this AML subtype (16.3% in MLL-PTD vs 3% in TCGA-AML (Po0.01) and 3.2% in a meta-analysis of 1102 AML 24 (Po0.0001)). Interestingly, although STAG2 mutations were found as early clonal mutations in our cohort with mean VAFs of around 0.4, these mutations were lost at relapse in two of the patients (Figure 4b-d) , suggesting that maintenance of the STAG2 mutation may not be required for relapse. Consistent with the notion of a functional overlap between mutations of the cohesin genes, a mutually exclusive pattern was noted (Figure 4e and f) . Interestingly, a mutually exclusive pattern was also noted between STAG2 and the splicing factor U2AF1. The underlying mechanism behind this observation is currently unknown and requires further studies. In addition, a mutually exclusive pattern was noted between STAG2 and the other major AML drivers (except for IDH2 which tended to co-occur with STAG2) (Supplementary Figure 6) .
The RNA processing pathway was also strikingly altered in MLL-PTD patients. The most prominently mutated genes within this category were the splicing factors. They included U2AF1 (12.5%, S34F/Y), SRSF2 (2.5%, hotspot position P95, Supplementary  Figure 10 ), SF3A1 (5%), ZRSR2 (2.5%), DHX15 (1%) and CWC22 (1%). We and others have hallmarked their importance by noting their high frequency (460%) in myelodysplastic syndromes. 25, 26 Genes encoding RNA helicases (DDX10 (5%) and HELZ (3%)) were also frequently altered in the prevalence cohort. This family of proteins is involved in the regulation of RNA splicing, ribosome/ spliceosome assembly and initiation of translation. 27 Mutations were also identified in RNA processing and degradation proteins DIS3 28 (9%) and SMG1 (2.5%).
MGA is a potential tumor suppressor Another highly mutated novel gene was MGA, an incompletely studied gene with a mutation frequency of 9% in MLL-PTD AML (Figure 5a ). It encodes a MAX-interacting protein and is believed to act as a transcription factor that suppresses MYC binding to its target. By in silico analysis, we found that MGA was expressed in normal myeloid hematopoietic cells and AML (Supplementary Figure 11) . Further data mining of TCGA sequencing projects revealed a high frequency of inactivating mutations of the MGA gene in a variety of cancers (Figure 5b) , suggesting a potential pan (e) Mutations driving cell proliferation are replaceable during diagnosis and relapse. Upper pair, in patient CH002, mutant NRAS carrying subclone was found at leukemic diagnosis, this subclone subsequently was eliminated by chemotherapy. However, the founding clone survived during the chemotherapy, gained a FLT3 D839G mutation, and this alternative FLT3 carrying subclone (FLT3 D839G) expanded and became the dominant clone at relapse. Lower pair, in patient GR019, leukemia at diagnosis harbored two different FLT3-ITD carrying subclones, both were eliminated by chemotherapy. The founding clone survived the chemotherapy, and an alternative subclone derived from the founding clone harbored a different FLT3-ITD mutation, which subsequently appeared at relapse. cancer tumor suppressor role of this gene. To interrogate functionally its role in leukemogenesis, lentiviral constructs containing either shRNA or CRISPR-sgRNA targeted to different regions of the MGA gene were generated (Supplementary Table 9 ). MLL-PTD containing AML cell line EOL-1 29 was infected with the shRNA/sgRNA viral particles. Stable cell lines were selected with puromycin, and the silencing ability of the shRNAs towards MGA was assessed by western blot and real-time PCR (Figure 5c and d, Supplementary Table 10 ). Methylcellulose colony-formation assay was subsequently employed to evaluate the effect of silencing MGA. An increase of colony number (~30%) was observed in MGA silenced cell lines (Figure 5c ). Similarly, silencing of MGA by either siRNA or CRISPR-sgRNA modestly increased the colony formation (Figure 5e-g ). Congruently, silencing of MGA by CRISPR-sgRNA consistently enhanced the in vivo xenograft cell growth in NSG mice (Figure 5h and i, Supplementary Figure 12 ). In addition, western blot analyses revealed the elevation of p-RB and Cyclin E1 in the MGA silenced cells (Figure 5d, Supplementary Figure 12) , indicative of a proliferative advantage conferred by the silencing of MGA.
As mentioned above, MGA may be a potential regulator of the MYC pathway. We, therefore, examined whether silencing of MGA alters MYC transcriptional activity. Luciferase reporter assay was carried out in 293FT cells stabilized with either scramble or shRNAtargeting MGA. A fourfold increase in luciferase activity was observed in MGA silenced cells when compared with nontargeting shRNA controls (Figure 5j ). Furthermore, Kaplan-Meier survival analysis of the TCGA-AML patients suggests that MGA mRNA expression level is correlated with overall patient survival. AML patients with lower levels of MGA in their leukemic samples had a worse outcome compared with those whose leukemic cells expressed higher levels of MGA (Figure 5k) . Collectively, our results suggest that MGA may function as a potential tumor-suppressor in AML.
Initiating mutations often persist at remission Strikingly, we observed that some early clonal mutations in DNMT3A, TET2, IDH1/2, U2AF1 (herein termed remission-persisting mutations) were retained with high VAF in a large proportion of patients' remission samples (29%, 8 of 28 patients); in contrast, neither the MLL-PTD (determined by real-time RT-PCR (sensitive range from 1:100-1:10 000, see Weisser et al. 30 ) and by relative copy number (RCN) analysis) as well as those associated with a relatively later subclonal mutations (for example, FLT3/NRAS, Figure 6a and Supplementary Figure 13) were detected. The fact that DNMT3A/TET2/IDH1/2/U2AF1 mutations were detected at both diagnosis and complete clinical morphological remission (determined by normal morphology/cytogenetics, % blasts and further supported by the disappearance of other mutations found at diagnosis) suggests that these mutations are most likely present prior to malignant transformation. 10, 12, 31 Notably, recent studies from several research groups have revealed a high prevalence of hematologic cancer-related gene (DNMT3A, TET2, ASXL1) mutations in normal individuals as they aged [31] [32] [33] [34] [35] and these mutations are associated with an increased risk for the development of hematologic cancer. Collectively, our observations suggest that chemotherapy eliminated the malignant leukemic cells and reverted these patients back to a pre-leukemic (clonal hematopoiesis) instead of a completely normal state (polyclonal hematopoiesis). These remission-persisting mutations carrying clones may act as a reservoir for subsequent relapse. 36 Ordering of mutations in MLL-PTD AML To identify the mutation order of the MLL-PTD aberration in relation to other mutations, we performed copy number analysis of MLL-PTD. The tandem duplication of MLL gene leads to a copy number gain of the affected exons. By analyzing the sequencing read depth of each exon (normalized with the local and global capturing efficiency, Supplementary Figures 14-16 ), the RCN of each exon of the MLL gene can be calculated and the proportion of mutation carrying cells inferred (see Supplementary Results for full discussion). Guided by this notion, we calculated the RCN value of each exon of the MLL gene for 28 paired MLL-PTD samples with matched remission control. For most of the samples, we found a mean RCN of~1.5 for exons 3-9 and a RCN value of 1 in the other exons (Figure 6b and c) . At the same time, a control analysis was performed with TCGA-AML patient's exomesequencing data (excluding the nine MLL-PTD patients) and 200 ALL patients targeted sequencing data (Supplementary Figure 15) , and 'low' groups were defined by 15% higher than the median or 15% lower than the median, respectively. which revealed a RCN value of~1 in all MLL exons (Figure 6c ). Taken together, the observed RCN of duplicated MLL-PTD exons of 1.5 (Figure 6c ) suggests the presence of MLL-PTD as a clonal mutation in most of the MLL-PTD patients.
MLL-PTD is a highly specific AML driver Our observation of MLL-PTD as an early clonal driver mutation in AML raises an intriguing question of whether MLL-PTD may serve similar roles in other cancer types. MLL-PTD manifests as a tandem duplication of exons 3-9 of MLL gene. The length of exons 3-9 of MLL is~12.5 kb, suggesting that SNP-arrays can identify the MLL-PTD alteration. Indeed, canonical MLL-PTD involving exons 3-9 was identified in the EOL-1 (known to carry MLL-PTD mutation 29 ), as well as the Kasumi-6 AML cell line ( Supplementary  Figures 15c and d) . Furthermore, AML samples known to have MLL-PTD can also be detected by analysis of the TCGA SNP-array database (Supplementary Figure 15e) , suggesting that SNP-array is a valid platform for the detection of MLL-PTD. Upon further examination of 1000 different cancer cell lines in CCLE, 10 000 different cancer samples in TCGA SNP-array database (Broad-Firehose-standard-data-run2015_04_02) and a panel of 2792 samples of different cancer types in the Tumorscape SNParray database, we conclude that the gain of exon 3-9 in MLL, as a clonal mutation, is likely only present in AML, suggesting that MLL-PTD is a rare and highly specific AML driver.
DISCUSSION
In this study, we found that multiple mutations co-occur with MLL-PTD and mutations are usually acquired in a sequential manner. A potential ordering for acquisition of mutations was proposed (IDH2/DNMT3A/U2AF1/TET2 → MLL-PTD → RAS-RTK) based on the following reasons: #1, real-time-PCR (Figure 6a) showed that MLL-PTD was absent in remission while mutations of IDH2, DNMT3A, TET2 and U2AF1 were still retained with a high VAF. This suggests that MLL-PTD was acquired after mutations of IDH2, DNMT3A, TET2 and U2AF1; #2, MLL-PTD is highly stable during disease progression as compared with mutations of the RAS-RTK. In a previous study characterizing 46 AML patients carry MLL-PTD mutation at diagnosis, MLL-PTD persisted in 43 of these individuals at relapse. 30 On the other hand, as shown in Figure 3 , RAS-RTK mutations frequently exist as subclonal mutations and tend to be unstable during disease progression. These observations support a notion that MLL-PTD was acquired prior to RAS-RTK. Taken together, the above reasoning suggests MLL-PTD is acquired after those remission-persisting, initiating mutations (IDH2, DNMT3A, TET2 and U2AF1), but prior to lesions of the proliferation-related driver (Figure 6d ), highlighting its critical role in the development of full-blown AML. Indeed, our observations and inference of clonal early/late mutations are consistent with recent reports of healthy elderly individuals carrying functionally inactivating DNMT3A/TET2 mutations, [31] [32] [33] [34] as well as previous studies from the DNMT3A and TET2 knockout mouse model. [37] [38] [39] These studies point to a model where a pre-malignant founder clone is formed following acquisition of an initiating mutation and where the subsequent gain of cooperating mutations in these pre-leukemic cells leads to the onset of leukemogenesis. In this paradigm, MLL-PTD can thus be viewed as one of the early cooperating mutations. Interestingly, one of the most frequently mutated AML genes, NPM1, is mutually exclusive with MLL-PTD. Mutations of NPM1 are usually present as early clonal mutations in AML blasts, but are absent in normal appearing elderly individuals who can carry mutations of DNMT3A and TET2. [32] [33] [34] 40 This observation implies that, similar to MLL-PTD, NPM1 mutations can also be considered as one of the early cooperating mutations. In this regards, MLL-PTD and NPM1 may be involved in similar pathways to trigger AML as inferred from their mutually exclusive pattern.
Based on our observations and previous studies of normal elderly individuals, [32] [33] [34] 40 a potential molecular boundary can be defined to distinguish the leukemic and pre-leukemic stage: the initiating mutations (DNMT3A and so on) were detected in both pre-and bonafide leukemia as well as in 10% of normal individuals over the age of 65, [32] [33] [34] 40 whereas the early mutations of RUNX1, WT1, NPM1, STAG2 and so on were usually only found in frank leukemic blast cells (and in myelodysplastic syndromes/myeloproliferative neoplasms). Therefore, these early mutations (RUNX1, WT1, NPM1 and so on) rather than the initiating mutations, will likely be the most informative markers for the measurement of minimal-residual disease. 41 In the design of targeted therapeutic strategies for cancer patients, high priority should be accorded to the 'trunk' mutations that are present in the majority of the cancer cells. The molecular timeline model established here suggests that, despite the observed high prevalence of RAS-RTK mutations in MLL-PTD AML, most of these mutations are present in only a fraction of the cancer cells. Thus, targeting these late subclonal events may have only limited therapeutic value.
During submission of our manuscript, another article on MLLrearranged AML appeared; 42 this article identified LOC100289656 as a specific MLL fusion AML marker and focused on analysis of the transcriptome and mutation of MLL fusion AML patients. Conversely, our study focuses on MLL-PTD instead of MLL fusion, which distinguishes our study from their report.
In summary, our analysis of the mutational landscape of 85 MLL-PTD AML patients revealed the sequential pattern of mutational acquisition and a number of co-occurring mutations. This study provides a detailed mutational profile and approximate timeline for a unique AML subtype, which may guide the development of more effective therapeutic approaches and further pave the way for AML personalized therapeutic strategies. 
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